The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Patent covers control and manufacture of TYK2, A very small abstract.
'The TYK2 kinase-inhibiting activities of the crystalline forms of the compound of formula (1) can be made use of in various methods of treating diseases where TYK2 plays a part in the development or progression of the disease. The various uses of the compound of formula (1) typically involve bringing the compound into contact with a TYK2 kinase. The inhibition of the TYK2 kinase may take place either in vitro or in vivo.
Accordingly, in further embodiments, the invention provides:
6.1 A crystalline form of the compound of formula (1) as defined in any one of Embodiments 1.0 to 5.2 for use as an inhibitor of TYK2 kinase.
6.2 A crystalline forms of the compound of formula (1) as defined in any one of Embodiments 1.0 to 5.2 for use in medicine.
The inhibition of TYK2 kinase preferably takes place in vivo as part of a therapeutic treatment of a disease or condition in which TYK2 kinase is implicated.
The compound of formula (1) is a selective TYK2 inhibitor and is considerably more active against TYK2 than JAK2 and JAK3 kinases. The compound has relatively poor activity against a wide range of other kinases and, in particular, kinases that are generally recognised as targets for anti-cancer therapy. Thus, for example, the compounds have relatively little activity against Chk1 kinase, Aurora kinases, PKB (Akt) kinase and cyclin dependent kinases (CDK kinases) which are involved in cell cycle progression. A lack of activity against kinases typically considered to be anti-cancer targets is beneficial in compounds that may be used in chronic treatment of inflammatory and autoimmune diseases for example.
It is envisaged on the basis of their TYK2 inhibiting activity that the crystalline forms of the compound of formula (1) as defined in any one of Embodiments 1.0 to 5.2 will be useful in treating at least some of the diseases and disorders discussed below, including inflammatory diseases or conditions, immunological diseases or conditions, autoimmune diseases, allergic diseases or disorders, transplant rejections (allograft transplant rejections); Graft-versus host disease; treating sepsis and septic shock.
There exists hours of reading on the subject.
A great find who ever posted originally and a great post whoever subsequently reposted.
Regards
worth a read and apologies if posted before.
https://www.edisongroup.com/publication/treading-the-tyk2-trail/29435/
Morning citizen, fully agree.
I’ve said so many times, the majority of LTH’s have 10 bagged or more already, on no real news. No income (hnwi are only recently), flt3 given back, Sierra dragging their heels (IMO). Yes patents, yes Nature articles etc but no proper deals or revenue. Until this year, dilution most years. Yet we are all sat on huge paper profits.
There’s absolutely no reason we couldn’t be somewhere nearer 15p/20p/Thoth2’s 28p before the life changing RNS drops. More clarification of the patent, more research papers, more findings by excellent posters here. We could well be 20p+ before we potentially 10 bag on the kind of deal we deserve
GLA
Morning all, firstly I must congratulate Madd/Timbo for their stunning find & the excellent thoughts & interpretations noted here by our illustrious posters. Some of the previously well perused points were very exciting indeed; in-halables, pill forms, mass manufacturing & new contacts/"inventors" - so much to take in.
Secondly whilst I have to admit to finding the whole area of patents completely mystifying - I think I'll stick to the science as that is what underpins everything IMHO:
That being said there are some enticing pointers on our latest science within the patent which I plan to delve into in the coming days.
For what its worth, an orderly release of news installments from Sareum is what I envisage over the coming weeks; well structured & organised providing maximum SP stability whilst maintaining the march toward the endgame.
In addition, some interesting info contained herein for those who fancy a read:
Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?
https://www.mdpi.com/2072-6694/13/20/5204
Exciting times indeed.
ATB